[6-K] GSK plc Current Report (Foreign Issuer)
Filing Impact
Filing Sentiment
Form Type
6-K
GSK plc reported routine insider transactions on a Form 6‑K, disclosing that senior executives increased their interests through dividend reinvestment on 2025-10-10. The reinvestments followed dividends paid on 9 October 2025 and were executed in company plans on the London Stock Exchange and, for ADSs, the New York Stock Exchange.
Most entries reflect an increase in notional interest within the Deferred Annual Bonus Plan at £16.4000 per Ordinary Share, including the CEO 3,924 shares, the CFO 1,264 shares, and other executives such as Luke Miels 1,670 shares and Regis Simard 1,134 shares. One ADS transaction shows 417 ADSs at $43.4400 for Shobie Ramakrishnan on the NYSE.
Separately, the CEO acquired 8,786.741 Ordinary Shares at £16.4000 under the Performance Share Plan, which is subject to a 2‑year holding period. Additional small ISA purchases include David Redfern 20 shares at £16.3499 and the Company Secretary 17 shares at £16.3499.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of October 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Emma
Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
1,355
|
|
||
|
|
£16.4000
|
1,531
|
|
||
|
|
£16.4000
|
1,038
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
3,924
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Julie
Brown
|
|||
|
b)
|
Position/status
|
Chief
Financial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
680
|
|
||
|
|
£16.4000
|
584
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
1,264
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Diana
Conrad
|
|||
|
b)
|
Position/status
|
Chief
People Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
152
|
|
||
|
|
£16.4000
|
386
|
|
||
|
|
£16.4000
|
246
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
||||
|
Aggregated
volume
Price
|
784
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
James
Ford
|
|||
|
b)
|
Position/status
|
SVP
and Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
239
|
|
||
|
|
£16.4000
|
237
|
|
||
|
|
£16.4000
|
391
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
867
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Sally
Jackson
|
|||
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
242
|
|
||
|
|
£16.4000
|
149
|
|
||
|
|
£16.4000
|
133
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
524
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Luke
Miels
|
|||
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
365
|
|
||
|
|
£16.4000
|
578
|
|
||
|
|
£16.4000
|
727
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
1,670
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Shobie
Ramakrishnan
|
|||
|
b)
|
Position/status
|
Chief
Digital and Technology Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN: US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in ADSs following the re-investment of
dividends paid to shareholders on 9 October 2025 on ADSs held in
the Company's Deferred Annual Bonus Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$43.4400
|
119
|
|
||
|
|
$43.4400
|
112
|
|
||
|
|
$43.4400
|
186
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
417
$43.4400
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
David
Redfern
|
|||
|
b)
|
Position/status
|
President,
Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
463
|
|
||
|
|
£16.4000
|
334
|
|
||
|
|
£16.4000
|
211
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
1,008
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Regis
Simard
|
|||
|
b)
|
Position/status
|
President,
Global Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
309
|
|
||
|
|
£16.4000
|
557
|
|
||
|
|
£16.4000
|
268
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
1,134
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Philip
Thomson
|
|||
|
b)
|
Position/status
|
President,
Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
188
|
|
||
|
|
£16.4000
|
311
|
|
||
|
|
£16.4000
|
175
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
674
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Deborah
Waterhouse
|
|||
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
427
|
|
||
|
|
£16.4000
|
482
|
|
||
|
|
£16.4000
|
290
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volum
Price
|
1,199
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Tony
Wood
|
|||
|
b)
|
Position/status
|
Chief
Scientific Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Increase
in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 9 October 2025 on Ordinary
Shares held in the Company's Deferred Annual Bonus
Plan
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.4000
|
594
|
|
||
|
|
£16.4000
|
202
|
|
||
|
|
£16.4000
|
271
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume
Price
|
1,067
£16.4000
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Emma
Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GSK
plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|
|
b)
|
Nature of
the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on Ordinary Shares held in the
Company's Performance Share Plan subject to a 2-year holding
period
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.4000
|
4,590.351
|
||
|
£16.4000
|
4,196.389
|
||
|
d)
|
Aggregated information
Aggregated volume
Price
|
N/A
(single transaction)
8,786.741
£16.4000
|
|
|
e)
|
Date
of the transaction
|
2025-10-10
|
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
David
Redfern
|
|||
|
b)
|
Position/status
|
President
Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on Ordinary Shares held within an
ISA
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3499
|
20
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Victoria
Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 9 October 2025 on Ordinary Shares held within an
ISA
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3499
|
17
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume
Price
|
|
||||
|
e)
|
Date
of the transaction
|
2025-10-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: October
15, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK PLC
OTC:GLAXF
GLAXF Rankings
GLAXF Latest SEC Filings
Feb 23, 2026
[6-K] GSK plc Current Report (Foreign Issuer)
Feb 23, 2026
[6-K] GSK plc Current Report (Foreign Issuer)
Feb 20, 2026
[6-K] GSK plc Current Report (Foreign Issuer)
Feb 20, 2026
[6-K] GSK plc Current Report (Foreign Issuer)
Feb 20, 2026
[6-K] GSK plc Current Report (Foreign Issuer)
GLAXF Stock Data
3.98B